XL 5q33

Deletion Probe

Order Number
Package Size
100 µl


XL 5q33

This product has been replaced by XL Del(5)(q33). Order Number D-5091-100-OG

Clinical Details

The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008) cytogenetic aberrations are observed in about 50 % of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

The 5q- syndrome is defined as a primary myelodysplastic syndrome (MDS) with del(5q) as the sole karyotypic abnormality and without excess of blasts. A commonly deleted region (CDR) was narrowed to an approximately 1.5-Mb interval at 5q32-q33 flanked by the DNA marker D5S413 and the GLRA1 gene. The RPS14 gene is a strong candidate gene for the 5q- syndrome based on evidence from several sources.

Clinical Applications

  • Myelodysplastic Syndrome (MDS)
  • Acute Myelogenous Leukemia (AML)


XL 5q33

XL 5q33 hybridized to lymphocytes. One normal interphase and metaphase are shown.

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal, indicating the deletion of the 5q33.


  • Boultwood et al (1994) Blood 84:3253-3260
  • Ebert et al (2008) Nature 451:335-339
  • Boultwood et al (2010) Blood 16:5803-5811


Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.